Format

Send to

Choose Destination
J Immunother Cancer. 2019 Nov 29;7(1):332. doi: 10.1186/s40425-019-0798-3.

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).

Author information

1
Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Via Mariano Semmola, 80131, Naples, Italy. paolo.ascierto@gmail.com.
2
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR, USA.
3
Cancer Immunoregulation Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
4
UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
5
Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Center in the Earle A. Chiles Research Institute at Providence Cancer Institute, Portland, Oregon, USA.
6
Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
7
National Institute of Health and Medical Research, INSERM, Cordeliers Research Center, Paris, France.
8
Unit of Medical Oncology, Hospital "San Giuseppe Moscati", Avellino, Italy.
9
Oncology Department, ASO Santa Croce e Carle Cuneo, Cuneo, Italy.
10
Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
11
Department of Gynaecologic Oncology, Executive Director, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
12
Department of Neurological Surgery, University of California San Francisco, Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
13
Department of Microbiology and Immunology Hollings Cancer Center, Medical University of South Carolina (MUSC), Charleston, SC, USA.
14
Uro-Gynaecological Department, Istituto Nazionale Tumori Fondazione G. Pascale, IRCCS, Naples, Italy.
15
Department of Pathology, Yale School of Medicine, Translational Immuno-oncology Laboratory, Yale Cancer Center, Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA.
16
The Koch Institute for Integrative Cancer Research at MIT and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
17
Medical Oncology, Fondazione Policlinico Universitario Gemelli, IRCCS, Rome, Italy.
18
Melanoma Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
19
Parker Institute for Cancer Immunotherapy Research Center, UCSF, San Francisco, California, USA. Lisa.Butterfield@ucsf.edu.
20
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Abstract

Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28-29 November, 2018, Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key presentations from this meeting are summarised in this report.

KEYWORDS:

Biomarkers; Checkpoint inhibitors; Combination therapy; Immunotherapy; Tumor microenvironment

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center